Ozempic was developed for type 2 diabetes, but it’s quickly become one of the most talked-about drugs in the world. So, how does it work? Who does it work for? And what happens when people stop taking it? We asked researcher Callen Goldsmith from the Faculty of Medicine, Dentistry & Health Sciences at UniMelb, to break it down: the science behind GLP-1 drugs, what we still don’t know, and why the next few years matter for access and equity. | The University of Melbourne